Dr Pawan G Nayak
Assistant Professor
Date of Joining: 04.11.2020
Department of Pharmacology
CURRENT ACADEMIC ROLE & RESPONSIBILITIES
- Handles Pharmacology for DPharm and MPharm students
- Provides training regarding standard procedures to be adopted in the laboratory
Pawan G Nayak is an Assistant Professor in the Department of Pharmacology at MCOPS
SUBJECTS CURRENTLY TEACHING
| Subject | Semester / Year |
|---|---|
| Pharmacology and Toxicology (Theory and Lab) | DPharm Part-II |
| Pharmacology Practicals II | 2nd semester MPharm |
| Research work | III and IV semester MPharm |
ACADEMIC QUALIFICATIONS
| Degree | Specialisation | Institute | Year of passing |
|---|---|---|---|
| PhD | Pharmaceutical Sciences | Manipal Academy of Higher Education | 2018 |
| MPharm | Pharmacology | Manipal University | 2008 |
| BPharm | --- | Manipal Academy of Higher Education | 2006 |
Experience
| Institution / Organisation | Designation | Role | Tenure |
|---|---|---|---|
| Department of Pharmacology, MCOPS | Assistant Professor | Teaching and Research | November 2020 |
| Department of Pharmacology, MCOPS | Senior Research Fellow in DST-SERB funded project | Research | July 2019 – October 2020 |
| Department of Pharmacology, MCOPS | Research Coordinator in industry funded projects | Research | May 2018 – June 2019 |
| Department of Pharmacology, MCOPS | Senior Research Fellow in DST-SERB funded project | Research | April 2016 – March 2018 |
| Department of Pharmacology, MCOPS | Research Scholar in industry funded project | Research | February 2009 – April 2016 |
Strategy to combat statin-induced diabetes and its complications.
July 2019 – October 2020
SERB under DST, GoI (Senior Research Fellow in DST-SERB funded project)
May 2018 – June 2019
Research Coordinator in industry funded projects (Under Dr. K. Nandakumar (PI), Professor, MCOPS for Jagadale Industries, Pvt. Ltd., Bengaluru)
Development of novel quercetin analogues intended for selective HDAC-8 inhibition as beneficial anti-cancer agents.
April 2016 – March 2018
Senior Research Fellow in DST-SERB funded project (SERB under DST, GoI)
Preclinical evaluation of new chemical entities for anticlastogenic activity
February 2009 – April 2016
Research Scholar in industry funded project (Bristol Laboratories Ltd., Bristol, UK)
AREAS OF INTEREST, EXPERTISE AND RESEARCH
Area of Interest
Pharmacology, Toxicology, Cellular and Molecular biology
Area of Expertise
Preclinical testing and cell-based assays for the evaluation of new chemical entities, formulations and ayurvedic preparations
Area of Research
Preclinical drug discovery in the following therapeutic areas – inflammation, wound healing, cardiometabolic, neurological and oncological disorders
Professional Affiliations & Contributions
- Life Member of Indian Pharmacological Society (IPS)
Total number of publications: 51
Please browse the following link- https://manipal.pure.elsevier.com/en/persons/pawan-g-nayak
Botrops derived hemocoagulase formulation a probable agent for diabetic wound healing
2020 Keni, R Gourishetti, K Kinra, M Nayak, P.G Shenoy, R Nandakumar, K Jagdale, R.N Raghavendra, K.V Ahmed, S.M.
3 Biotech, 10 (10), art. no. 443. DOI: 10.1007/s13205-020-02429-5
COVID-19: Emergence, Spread, Possible Treatments, and Global Burden
2020 Keni, R Alexander, A Nayak, P.G Mudgal, J Nandakumar, K
Frontiers in Public Health, 8, art. no. 216. DOI: 10.3389/fpubh.2020.00216
Medhya rasayana restores memory function against doxorubicin-induced cognitive decline: Possibly by its neuroprotective effect
2019 Gourishetti, K Ghetia, S Jacob, L., Mallik, S.B Nayak, P.G Kishore, A Nandakumar, K Alnaseer, S.M Hussain, S.M
Indian Journal of Pharmaceutical Education and Research, 53 (2), pp. S104-S111. DOI: 10.5530/ijper.53.2s.54
In vivo Evaluation of Two Thiazolidin-4-one Derivatives in High Sucrose Diet Fed Pre-diabetic Mice and Their Modulatory Effect on AMPK, Akt and p38 MAP Kinase in L6 Cells
Mudgal J Shetty P Nayak PG Kumar N Kishore A Kutty NG Nandakumar K Shenoy RR Rao CM Joseph A et al
Front Pharmacol. 2016 Oct 14;7:381
Female rats induced with mammary cancer as a relevant animal model for doxorubicin-induced chemobrain in vivo
Ramalingayya GV Nayak PG Shenoy RR Rao CM Nandakumar K
Clin Exp Pharmacol Physiol. 2016 Sep;43(9):862-3. doi: 10.1111/1440-1681.12596. No abstract available. Erratum in: Clin Exp Pharmacol Physiol. 2016 Oct;43(10):1017
Naringin and Rutin Alleviates Episodic Memory Deficits in Two Differentially Challenged Object Recognition Tasks
Ramalingayya GV Nampoothiri M Nayak PG Kishore A Shenoy RR Mallikarjuna Rao C Nandakumar K
Pharmacogn Mag. 2016 Jan;12(Suppl 1):S63-70. doi: 10.4103/0973-1296.176104.